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Background
RNA-based compounds are promising methods to inacti-
vate viruses. New specific hepatitis delta virus (HDV)-
derived ribozymes are natural molecules that can be engi-
neered to specifically target a viral RNA. We have designed
specific on-off adapted (SOFA) HDV-ribozymes targeting
the regions of the HIV-1 RNA in the Tat and Rev
sequences.
Results
We show that these SOFA-HDV ribozymes cleave their Tat
RNA target in vitro. They inhibit the Tat-mediated transac-
tivation of HIV-1 long terminal repeat by up to 62 and
86% in luciferase and beta-galactosidase assays, respec-
tively. Inactivation of transfected HIV pNL4-3 molecular
clone reached a fourfold inhibition by reverse tran-
scriptase assay of the supernatant and an almost undetec-
table Gag protein synthesis. In vivo RNA cleavage reached
66 and 86% for two of the tested ribozymes showing that
the decrease in HIV production is due to the direct decline
in spliced and unspliced viral RNA. These SOFA-HDV-
ribozymes were able to target four HIV-1 strains, showing
an extended potential to act on multiple HIV variants.
When transfected before HIV-1 infection, they prevented
incoming virus to be expressed.
Conclusion
Our results show that SOFA-HDV-ribozymes show a great
potential to target HIV and to be used as therapeutic
agents in gene therapy.
from Frontiers of Retrovirology: Complex retroviruses, retroelements and their hosts
Montpellier, France. 21-23 September 2009
Published: 24 September 2009
Retrovirology 2009, 6(Suppl 2):P47 doi:10.1186/1742-4690-6-S2-P47
<supplement> <title> <p>Frontiers of Retrovirology: Complex retroviruses, retroelements and their hosts</p> </title> <note>Meeting abstracts - A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1742-4690-6-S2-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1742-4690-6-S2-info.pdf</url> </supplement>
This abstract is available from: http://www.retrovirology.com/content/6/S2/P47
© 2009 Lainé et al; licensee BioMed Central Ltd. 